Albany, New York, April 29,
2015 : Market Research Reports Search Engine
(MRRSE), a leading portal offering business intelligence reports, has announced
the addition of a new report on the ovarian cancer therapeutics market with a
focus on Asia Pacific. The report is titled “Ovarian Cancer Therapeutics in
Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance
Despite New Launches”.
Currently, the therapies developmental pipeline is abuzz with
activity but the efficacy of these drugs is still below the expected standard.
Progress still needs to be made in improving the overall survival rates of
patients suffering from OC. Drugs candidates that show the most potential
currently are trebananib and olaparib. These two drugs will likely obtain the
regulatory nod during the forecast period of this report. Analysts forecast
that it will be a while before these drugs are able to achieve a significant
degree of market penetration. Moreover, the premium prices of these drugs will
further limit their acceptance.
Thus, new drug approvals cannot
be listed as a driver for the Asia Pacific ovarian cancer market. Growth will effectively occur as a
result of inflationary forces and the general increase in the pervasiveness of
ovarian cancer. The report forecasts that the revenues in the APAC OC market
will rise at a meager 5.1% CAGR through the forecast period, touching US$417.6
million by 2020.
The report estimates market revenues and size for the period
2013 to 2020 for key markets in the Asia Pacific region, namely, China, India,
Japan and Australia. The report begins with the coverage of the disease
epidemiology, treatment patterns and algorithms, as well as a detailed analysis
of the clinical trials at various stages. A pipeline analysis of the ovarian
cancer therapeutics market is yet another vital component of the report.
Findings of the report state that platinum-based
chemotherapy—more specifically paclitaxel and carboplatin regimens—is the
customary treatment, in the case of ovarian cancer that is sensitive to
platinum. This line of treatment is offered in the case of both first-time as
well as recurrent ovarian cancer. The initial treatment of the disease has
proven to be effective, with the vast majority of patients reporting remission
of their disease. However, the analysis also states that nearly all of these
cases experience a relapse – ultimately leading to mortality or the emergence
of platinum-resistant ovarian cancer (the prognosis for which is currently
poor).
The report identifies a wide gap in the current ovarian cancer
market for maintenance therapies. A pressing need is also felt for treatment
options that are more effective, especially in patients with platinum-resistant
OC.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease
Pathophysiology
2.1.1 Ovarian Cancer –
A Group of Distinct Diseases
2.1.2 Ovarian Cancer
is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and
Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited
Genetic Mutations
2.3.3 Greater Number
of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical
Conditions
2.4 Treatment
Algorithm
2.4.1 Surgery
2.4.2 First-Line
Chemotherapy
2.4.3 Maintenance
Therapy
2.5 Recurrent Disease
Send An Enquiry : http://www.mrrse.com/enquiry/112
3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated
Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin
4 Product Pipeline
4.1 Overview of
Pipeline by Phase and Route of Administration
4.2 Overview of
Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular
Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial
Duration
4.3.2 Clinical Trial
Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs
in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib
4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion
5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Overview
5.1.2 Treatment Use
Patterns and Revenues in Asia-Pacific Markets
5.2 India
5.2.1 Treatment Use
Patterns
5.2.2 Annual Cost of
Therapy
5.2.3 Market Forecast
5.3 China
5.3.1 Treatment Use
Patterns
5.3.2 Annual Cost of
Therapy
5.3.3 Market Forecast
5.4 Japan
5.4.1 Treatment Use
Patterns
5.4.2 Annual Cost of
Therapy
5.4.3 Market Forecast
5.5 Australia
5.5.1 Treatment Use
Patterns
5.5.2 Annual Cost of
Therapy
5.5.3 Market Forecast
5.6 Drivers and
Barriers
5.6.1 Drivers
5.6.2 Barriers
6 Deals
6.1 Licensing Deals
6.1.1 Clovis Oncology
Enters into Licensing Agreement with Pfizer for PF-01367338
6.1.2 PharmaMar Enters
into Licensing Agreement with Janssen for Yondelis
6.1.3 Hana Enters into
Licensing Agreement with Tekmira
6.1.4 AstraZeneca
Enters into Licensing Agreement with Merck for MK-1775
6.1.5 Tesaro Enters
into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
6.1.6 Oasmia Enters
into Licensing Agreement with Medison for Paclical
6.1.7 Orion Enters
into Agreement with Oasmia
6.1.8 Ohio University
Enters into Licensing Agreement with Phosplatin
6.1.9 Genta Enters
into Licensing Agreement with Daiichi Sankyo
6.1.10 Celldex Enters
into Licensing Agreement with the Ludwig Institute for Cancer Research
6.1.11 NanoCarrier
Enters into Licensing Agreement with Kowa for NC-6300
6.2 Co-development
Deals
6.2.1 Bristol-Myers
Squibb Enters into Co-development Agreement with Ono Pharma
6.2.2 Merck Enters
into Co-development Agreement with Endocyte for Cancer Drug
6.2.3 Pfizer Enters
into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre
6.2.4 Almac Discovery
Enters into an Agreement with Queen’s University Belfast for Drug Discovery
7 Appendix
7.1 All Pipeline Drugs
by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Pre-Registration
7.2 Market Forecasts
to 2020
7.2.1 Asia-Pacific
7.2.2 India
7.2.3 China
7.2.4 Japan
7.2.5 Australia
7.3 Abbreviations
7.4 Bibliography
7.5 Research
Methodology
7.5.1 Coverage
7.5.2 Secondary
Research
7.5.3 Primary Research
7.5.4 Therapeutic Landscape
7.5.5 Geographical
Landscape
7.5.6 Pipeline
Analysis
7.6 Expert Panel
Validation
7.7 Contact Us
7.8 Disclaimer
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
No comments:
Post a Comment